The Utility of the Comprehensive Complication Index in Demonstrating the Complication Burden and Predicting Length of Stay in Robot-Assisted Radical Prostatectomy

Clinical Genitourinary Cancer · Available online 1 Sep 2026 · In press · Journal article · DOI 10.1016/j.clgc.2026.102659

Authors (5)

Yunus Çolakoğlu, Deniz Noyan Özlü, Büşra Emir, Enes Yavuz, Ali Ayten

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Volume

24

Issue

8

Pages

102659

Year

2026

Citation

Çolakoğlu, Y., Özlü, D., Emir, B., et al. (2026). The Utility of the Comprehensive Complication Index in Demonstrating the Complication Burden and Predicting Length of Stay in Robot-Assisted Radical Prostatectomy. Clinical Genitourinary Cancer. https://doi.org/10.1016/j.clgc.2026.102659

Related articles

• Utility of Circulating Tumor DNA as a Monitoring Tool for Marker-Negative Germ Cell Tumors and Somatic Type Malignancies · Clinical Genitourinary Cancer · 2026 · Same journal
• Real-World Effectiveness and Tolerability of Belzutifan in Sporadic Clear Cell Renal Cell Carcinoma: A Retrospective Cohort Study With Exploratory Genomic Correlation · Clinical Genitourinary Cancer · 2026 · Same journal
• Exploration of the Challenges in the Management of Prostate Cancer in East Africa · Clinical Genitourinary Cancer · 2025 · Same journal
• Real-World Treatment Duration With First-line Enfortumab Vedotin Plus Pembrolizumab for Advanced Urothelial Cancer: A National Electronic Health Record Study · Clinical Genitourinary Cancer · 2026 · Same journal
• Immunophenotyping and Molecular Patterns of Prostate Cancer in East Africa: Diagnostic and Prognostic Implications—A Systematic Review · Clinical Genitourinary Cancer · 2026 · Same journal
• Impact of Age on Outcomes in Metastatic Non–Clear Cell Renal Cell Carcinoma: A Real-World TriNetX Analysis From the Global Society of Rare Genitourinary Tumors (GSRGT) · Clinical Genitourinary Cancer · 2026 · Same journal
• Efficacy and Safety of Every Other Week Gemcitabine and Docetaxel (GEMDOC) in Heavily Pretreated Metastatic Castration Resistant Prostate Cancer: A Retrospective Real-world Analysis · Clinical Genitourinary Cancer · 2026 · Same journal
• A Real-World Prospective Study of Comprehensive Genomic Testing in Patients With Metastatic Castration-Resistant Prostate Cancer · Clinical Genitourinary Cancer · 2025 · Same journal
• Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment in Metastatic Urothelial Cancer: A Randomized Phase II Study of Two Alternative Dosing Schedules · Clinical Genitourinary Cancer · 2025 · Same journal
• Why Has Prostate Cancer Research Lagged Behind? Advocacy, Biology, and the Road Ahead · Clinical Genitourinary Cancer · 2026 · Same journal